{"id":"NCT01484496","sponsor":"Human Genome Sciences Inc., a GSK Company","briefTitle":"A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)","officialTitle":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-11-16","primaryCompletion":"2015-02-13","completion":"2015-10-01","firstPosted":"2011-12-02","resultsPosted":"2017-07-25","lastUpdate":"2018-06-06"},"enrollment":839,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Systemic Lupus Erythematosus"],"interventions":[{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Belimumab 200 mg SC","otherNames":["BENLYSTAâ„¢"]},{"type":"DRUG","name":"Standard therapy","otherNames":[]}],"arms":[{"label":"Placebo plus standard therapy","type":"PLACEBO_COMPARATOR"},{"label":"Belimumab 200 mg SC plus standard therapy","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).","primaryOutcome":{"measure":"Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52","timeFrame":"Week 52","effectByArm":[{"arm":"Placebo SC","deltaMin":48.4,"sd":null},{"arm":"Belimumab 200 mg SC","deltaMin":61.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":207,"countries":["United States","Argentina","Austria","Belgium","Brazil","Bulgaria","Chile","Colombia","Croatia","Czechia","Denmark","France","Germany","Hungary","Italy","Japan","Malaysia","Mexico","Philippines","Poland","Portugal","Romania","Russia","Serbia","Singapore","Spain","Sweden","Taiwan","Thailand","Ukraine","United Kingdom"]},"refs":{"pmids":["39115551","38216728","37228028","34531304","33687069","33568389","33558436","29807477","29671280","28118533"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":280},"commonTop":["Viral upper respiratory tract infection","Headache","Nasopharyngitis","Urinary tract infection bacterial","Nausea"]}}